Abstract: A broadband tuning system includes a first chip and a second chip. The first chip includes a first light amplification region, a first forward grating region and a first backward grating region that are sequentially arranged in a first direction. The first light amplification region is configured to amplify a first light source and to turn on or turn off the first light source, and the first forward grating region and the first backward grating region are configured to tune the first light source. The second chip includes a second light amplification region, a second forward grating region and a second backward grating region that are sequentially arranged in a second direction. The second light amplification region is configured to amplify a second light source and to turn on or turn off the second light source, and the second forward grating region and the second backward grating region are configured to tune the second light source.

Abstract: Disclosed are an ATX inhibitor, a preparation method therefor, and the use thereof, which belong to the technical field of pharmaceutical chemistry. In particular, the ATX inhibitor is a compound having the structure of formula I?, or a pharmaceutically acceptable salt, an ester, an isomer, a solvate, a prodrug or an isotope marker thereof. Compared with the existing ATX inhibitor GLPG-1690, the ATX inhibitor has higher inhibitory activity, also has excellent efficacy, in vitro/in vivo pharmacokinetic properties and safety, and has broad clinical application prospects.

Abstract: An AK3287 formulation, and a preparation method therefor and an application thereof. In mass fraction, the formulation comprises: 0.05-20% of AK3287; 0-30% of an absorption enhancer; 5-99.95% of an oil-phase substance; 0-25% of an emulsifier; 0-5% of a preservative; and 0-70% of water, wherein the structure of AK3287 is shown in the drawing. AK3287 molecules in the formulation have high exposure in the skin, and the formulation can reduce the thickness of the skin at a scar and the ratio of the maximum thickness of the skin at the scar to the thickness of the normal skin; moreover, the relative density of TGF-? and type I collagen in the skin is reduced.

Abstract: The present disclosure provides an elastase inhibitor prodrug and use thereof, being a compound of formula I or a pharmaceutically acceptable salt, ester, isomer or solvate thereof, prodrugs or isotopically labeled compound. Compared with the compound 52 (control example) in WO 2018/175173 A1, the compound disclosed herein has the advantages of high pulmonary exposure and long half-life. The prodrugs of the present disclosure significantly increase the concentration and residence time of the active compound (control example) in the lungs with significant improvements in pharmacokinetics in vivo compared to the control example.

Abstract: The present disclosure provides the synthesis and application of respiratory syncytial virus inhibitor, being a compound of formula I or a pharmaceutically acceptable salt, ester, isomer, solvate, prodrug or isotope label thereof. Compared with the existing inhibitors, the compounds of formula I have the advantages of superior activity and higher exposure in vivo.

Abstract: Disclosed is a pharmaceutical unit dosage composition including a plurality of enteric coated micro pellets. Each enteric coated micro pellet includes a core bead, an optional first sealing layer, an API layer including a Compound (I) having the following structure or a pharmaceutically acceptable salt thereof, an optional second sealing layer, and an enteric coating layer. Also disclosed is a method for the treatment and prophylaxis of RSV diseases including providing a Compound (I) and administering to a patient in need thereof a therapeutically effective amount of the Compound (I) so that t½ of the Compound (I) is about 6 to 13 hours.

Abstract: The present disclosure provides a series of dihydroisoquinoline compounds or a pharmaceutically acceptable salt, ester, isomer, solvate, hydrate, prodrug, or isotopically labeled compounds thereof, having the structure of general formula I: (I). The compounds have an extremely strong activity for inhibiting Hepatitis B surface antigen and has an extremely strong activity for inhibiting Hepatitis B virus DNA. In addition, the compounds feature high bioavailability and can exhibit efficacy with a low dosage, which reduces the potential toxicity of the compounds.

Abstract: A broadband tuning system includes a first chip and a second chip. The first chip includes a first light amplification region, a first forward grating region and a first backward grating region that are sequentially arranged in a first direction. The first light amplification region is configured to amplify a first light source and to turn on or turn off the first light source, and the first forward grating region and the first backward grating region are configured to tune the first light source. The second chip includes a second light amplification region, a second forward grating region and a second backward grating region that are sequentially arranged in a second direction. The second light amplification region is configured to amplify a second light source and to turn on or turn off the second light source, and the second forward grating region and the second backward grating region are configured to tune the second light source.

Abstract: The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.

Abstract: Compositions containing the compound of general formula I: are disclosed. The compositions be used to prevent or treat hepatitis B virus infection.

Abstract: Compositions containing the compound of general formula I: are disclosed. The compositions be used to prevent or treat hepatitis B virus infection.

Abstract: A compound of general formula I: is disclosed. The compound be used to prevent or treat hepatitis B virus infection.

Abstract: The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.

Abstract: A compound of general formula I: is disclosed. The compound be used to prevent or treat hepatitis B virus infection.

Abstract: The invention discloses 20,23-modified novel derivatives of 16-membered demycarosyltylonolide antibiotics, which are useful against bacterial and mycoplasmic pathogens in humans and animals. Also claimed are pharmaceutical compositions of such derivatives and their use in treating bacterial and mycoplasmic infections in humans and animals.

Abstract: The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.

Abstract: The invention discloses 20,23-modified novel derivatives of 16-membered demycarosyltylonolide antibiotics, which are useful against bacterial and mycoplasmic pathogens in humans and animals. Also claimed are pharmaceutical compositions of such derivatives and their use in treating bacterial and mycoplasmic infections in humans and animals.

Abstract: The invention discloses 20,23-modified novel derivatives of 16-membered demycarosyltylonolide antibiotics, which are useful against bacterial and mycoplasmic pathogens in humans and animals. Also claimed are pharmaceutical compositions of such derivatives and their use in treating bacterial and mycoplasmic infections in humans and animals.

Abstract: An integral chip is disclosed by embodiments of the present disclosure, including: two mono-mode vertical coupling gratings, two modulation modules, one 2×1 multi-mode interference coupler, and one dual-mode vertical coupling grating. The integral chip is capable of operating in dual wavelengths and dual polarization states by combination of polarization multiplexing and wavelength division multiplexing so as to realize modulation of complex formats and to enhance data modulation rate.

Abstract: The present invention relates to novel pyridine or pyrimidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors. The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat disorders associated with chemokine receptor modulation.